Expression of p53 in adrenocortical tumours: Clinicopathological correlations

Journal of Pathology

Volumn 181, Issue 2, 1997, Pages 146-152

  McNicol, A M ^a   Nolan, C E ^a   Struthers, A J ^a   Farquharson, M A ^a   Hermans, J ^b   Haak, H R ^c  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Diaconessehuis ^*  (Netherlands)

Author keywords

Adrenal cortex; Immunohistochemistry; Neoplasm; p53 gene; PCR SSCP; Ploidy; Survival

Indexed keywords

PROTEIN P53;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PLOIDIES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031029337     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199702)181:2<146::AID-PATH744>3.0.CO;2-7     Document Type: Article

References (26)

1. Yano T, Lineham M, Anglard P, et al. Genetic changes in adrenocortical carcinomas. J Natl Cancer Inst 1989; 81: 518-523.
2. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747-752.
3. Srivaslava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
4. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.
5. Harlwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543-546.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
7. Pietenpol JA, Vogelstein B. No room at the p53 inn. Nature 1993; 365: 17-18.
8. Schmitt FC, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995; 176: 233- 241.
9. Mazars R, Pujol P, Mauadelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991; 6: 1685-1690.
10. Nakamura T, Yana I, Kobayashi T, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992; 83: 1293-1298.
11. Andersen TI, Holm R, Nesland JM, Hamdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993; 68: 540-548.
12. Silvestrini R, Benini E, Daidone MG, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965-970.
13. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993; 54: 408-410.
14. Lin S-R, Lee Y-J, Tsai J-H. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 1994; 78: 483-491.
15. Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78: 790-794.
16. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ, Activating mutations for transformation by p53 produce a gene product that forms an hsc70- p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.
17. Van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985; 55: 766-773.
18. Haak HR, Cornelisse CJ, Hermans J, Cobben L, Fleuren GJ, Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma. Br J Cancer 1993; 68: 151-155.
19. Mathews DE, Farewell V. Using and Understanding Medical Statistics. Basel: Karger, 1985.
20. Haak HR, Hermans J, Van de Velde CJH, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951.
21. Fujimo M, Dosaka-Akita H, Kato M, Kinoshita I, Akie K, Kawakami Y. Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. Am J Clin Pathol 1995; 104: 319-324.
22. Jeffers MD, Farquharson MA, Richmond JA, McNicol AM. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol 1995; 177: 65-70.
23. Sidransky D, Mikkelsen T, Schwecheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847.
24. McManus DT, Yap EPH, Maxwell P, Russell SEH, Toner PG, McGee JO'D. p53 expression mutation, and allelic deletion in ovarian cancer. J Pathol 1994; 174: 159-168.
25. Caleffi M, Teague MW, Jensen RA, et al. p53 gene mutations and steroid receptor status in breast cancer. Cancer 1994; 73: 2147-2156.
26. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-224.